BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine (Bergen, Norway, August 31 to September 2, 2009)
PARIS--(BUSINESS WIRE)--Aug 28, 2009 - Regulatory News:
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
Medical applications of nano- and microtechnology are undergoing unprecedented growth worldwide, with the first drugs based on these platforms now reaching the market. By positioning itself within this sector, BioAlliance Pharma is forging a reputation as a pioneer in France and the rest of Europe. The company's proprietary nanoparticle technologies enable it to offer innovative therapeutics solutions for parenteral or oral administration in oncology, infectious diseases and supportive care.
During this interdisciplinary symposium, BioAlliance Pharma will present its latest advances in the field of chemotherapy - notably its slow-release nanoparticle system for orally administered irinotecan and the "Transdrug" parenteral system. The symposium also constitutes an opportunity for the company to develop its network of experts with particular R&D expertise in these new modes of drug delivery.
About the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine
The "French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine" is being organized with the support of the French Embassy in Oslo and the Franco-Norwegian Foundation for Research, Innovation and Industrial Development (FFN-FFS).
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma (Paris:BIO) is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).
Contact: BioAlliance Pharma SA
Dominique Costantini MD, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
Posted: August 2009
